0.77
+0.04139999(+5.72%)
Currency In USD
| Previous Close | 0.72 |
| Open | 0.74 |
| Day High | 0.79 |
| Day Low | 0.72 |
| 52-Week High | 64.8 |
| 52-Week Low | 0.38 |
| Volume | 203,140 |
| Average Volume | 254,077 |
| Market Cap | 8.91M |
| PE | 0.26 |
| EPS | 2.98 |
| Moving Average 50 Days | 0.92 |
| Moving Average 200 Days | 0.76 |
| Change | 0.04 |
If you invested $1000 in AEON Biopharma, Inc. (AEON) since IPO date, it would be worth $1.15 as of December 11, 2025 at a share price of $0.765. Whereas If you bought $1000 worth of AEON Biopharma, Inc. (AEON) shares 1 year ago, it would be worth $11.81 as of December 11, 2025 at a share price of $0.765.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
GlobeNewswire Inc.
Nov 20, 2025 1:30 PM GMT
- First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a bioph
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
GlobeNewswire Inc.
May 19, 2025 8:05 PM GMT
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indic
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
GlobeNewswire Inc.
Apr 25, 2025 8:05 PM GMT
IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic ind